author-photo

Rebecca Liguori

Harvard University

6

Papers

357

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

2016 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (326)
Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

2015 Blood
Show All
- Source
- Cite
- Save
Citations (9)
Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (3)